Novel Biomarkers for Evaluation of Endothelial Dysfunction

• Tipo: Artigo em Revista Científica Internacional
• Data: 2020

Autores

Leite, AR (Autor) Outra; Borges Canha, M (Autor) FMUP; Cardoso, R (Autor) FMUP; Neves, JS (Autor) FMUP; Castro Ferreira, R (Autor) FMUP; Leite-Moreira AF (Autor) FMUP

Revista

A Revista está pendente de validação pelos Serviços Administrativos.

Título: ANGIOLOGY

Vol. 71

Páginas: 397-410

ISSN: 0003-3197

Editora: SAGE Publications

Indexação

ISI Web of Knowledge - 95 Citações

Scopus - 106 Citações

Outras Informações

ID Authenticus: P-00R-WQ5

DOI: 10.1177/0003319720903586

Abstract (EN): Endothelial dysfunction is one of the earliest indicators of cardiovascular (CV) dysfunction, and its evaluation would be of considerable importance to stratify CV risk of many diseases and to assess the efficacy of atheroprotective treatments. Flow-mediated dilation is the most widely used method to study endothelial function. However, it is operator-dependent and can be influenced by physiological variations. Circulating biomarkers are a promising alternative. Due to the complexity of endothelial function, many of the biomarkers studied do not provide consistent information about the endothelium when measured alone. New circulating markers are being explored and some of them are thought to be suitable for the clinical setting. In this review, we focus on novel biomarkers of endothelial dysfunction, particularly endothelial microparticles, endocan, and endoglin, and discuss whether they fulfill the criteria to be applied in clinical practice.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 14